An antiphospholipid syndrome blood test panel combines three established marker groups: lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies. Together, these tests help evaluate whether antiphospholipid antibodies may be linked to a blood clot, small-vessel disease, or a defined pregnancy complication. They do not diagnose APS without a compatible clinical history.
The panel is more complicated than a routine positive-or-negative blood test. Lupus anticoagulant is detected through clotting assays, while anticardiolipin and anti-beta-2 glycoprotein I are measured with antibody immunoassays. Anticoagulant medicines can distort lupus anticoagulant results, and low antibody levels may be temporary. A clinically relevant result generally needs confirmation on a second sample at least 12 weeks later. The strongest interpretation states which markers are positive, their level and isotype, whether the findings persist, and what documented clinical event they accompany. Missing one marker group can leave an important gap in risk assessment.
- A complete established panel includes lupus anticoagulant, anticardiolipin IgG/IgM, and anti-beta-2 glycoprotein I IgG/IgM.
- APS cannot be diagnosed from antibodies alone; a qualifying clinical manifestation is also required.
- Positive established markers usually need repeat confirmation at least 12 weeks later.
- Warfarin, heparin, and direct oral anticoagulants can interfere with lupus anticoagulant testing.
- Persistent lupus anticoagulant and multiple-marker positivity often indicate a higher-risk profile than a single weak antibody.
Table of Contents
- Components of the APS Panel
- When the Panel Is Appropriate
- How Lupus Anticoagulant Testing Works
- How Antibody Results Are Reported
- Combining Results Into an Antibody Profile
- From Positive Tests to APS Diagnosis
- Timing, Medications, and Common Testing Errors
- What to Do With the Panel Results
Components of the APS Panel
The established APS panel covers three different laboratory marker groups. Ordering all three matters because they detect related but not identical antibody effects.
| Marker group | What the laboratory measures | Typical report |
|---|---|---|
| Lupus anticoagulant | Phospholipid-dependent interference in clotting assays | Negative, positive, or indeterminate with method comments |
| Anticardiolipin antibodies | IgG and IgM antibody binding to cardiolipin-associated targets | Numerical values with units and reference ranges |
| Anti-beta-2 glycoprotein I antibodies | IgG and IgM binding to beta-2 glycoprotein I | Numerical values with units and reference ranges |
Lupus anticoagulant (LA) is a laboratory effect rather than one named antibody. It prolongs certain phospholipid-dependent clotting times in the test tube, despite being associated with thrombosis in the body. The name does not mean the person has lupus, and it does not mean the person is protected from clotting.
Anticardiolipin (aCL) testing usually measures both IgG and IgM. IgG often has a stronger association with APS manifestations than isolated low-level IgM, although persistent moderate or high IgM can still matter. Some laboratories add IgA, but IgA is not part of the current established laboratory classification domains.
Anti-beta-2 glycoprotein I (anti-β2GPI) testing also measures IgG and IgM. Beta-2 glycoprotein I is a blood protein that binds to negatively charged phospholipid surfaces. Antibodies against it are more antigen-specific than the broad name “antiphospholipid” suggests.
A commercial “APS panel” may omit LA, include only one isotype, or add non-criteria antibodies. The order name is not enough. The report should be checked line by line. A complete comparison is available in the antiphospholipid IgG panel and antiphospholipid IgM panel guides.
Some institutions collect the panel in more than one tube because coagulation testing and antibody immunoassays have different specimen requirements. LA testing commonly uses citrated plasma, while solid-phase antibodies may use serum or plasma according to the platform. A missing or underfilled citrate tube can prevent valid LA analysis even when the antibody portion is completed. This is one reason a report may contain final anticardiolipin values but show lupus anticoagulant as canceled, unsuitable, or not performed.
When the Panel Is Appropriate
Testing is most informative when there is a reasonable clinical suspicion of APS. It is not a general screening panel for fatigue, headache, or family history alone.
Common reasons to order the panel include:
- An unprovoked venous thromboembolism, especially at a younger age
- Recurrent thrombosis or thrombosis in an unusual site
- Arterial thrombosis, such as ischemic stroke, without a sufficient explanation
- Small-vessel thrombosis or organ findings that may fit APS
- Defined recurrent pregnancy loss, fetal death, or early delivery caused by severe placental disease
- Systemic lupus erythematosus with a relevant clinical concern
- A prolonged clotting test that raises suspicion for lupus anticoagulant
- Thrombocytopenia, heart valve disease, livedo, or other findings when the overall picture suggests APS
Pretest probability matters because antiphospholipid antibodies can occur transiently or in people who never develop APS. Broad testing in a low-risk population increases the chance that a weak, incidental result will be mistaken for disease.
The clinical event should be documented before the laboratory result is allowed to redefine it. A deep vein thrombosis requires imaging confirmation. A stroke diagnosis should distinguish ischemia from bleeding and identify competing cardiac or vascular causes. Pregnancy records should include gestational age, ultrasound or pathology findings, maternal blood pressure, and the reason for delivery.
Testing may be less useful when a clot has a strong temporary explanation and the result would not change care. Even then, individual factors can justify evaluation—for example, recurrent events, a known autoimmune disease, or a thrombosis pattern unusual for the provoking factor.
Children, pregnant patients, hospitalized patients, and people already taking anticoagulants may need specialized timing and interpretation. The question is not simply whether blood can be drawn, but whether the result will be valid and useful.
How Lupus Anticoagulant Testing Works
LA testing is the most technically sensitive part of the panel. No single assay detects every lupus anticoagulant, so laboratories generally use at least two test systems based on different principles. Common choices are dilute Russell viper venom time (dRVVT) and an LA-sensitive activated partial thromboplastin time (aPTT).
The laboratory process usually includes three concepts:
- Screening: a low-phospholipid test checks whether clotting is prolonged.
- Mixing or inhibitor assessment: patient plasma may be mixed with normal plasma to see whether the prolongation behaves like an inhibitor rather than a factor deficiency.
- Confirmation: excess phospholipid is added. Shortening of the clotting time supports phospholipid-dependent inhibition.
Laboratories may use integrated algorithms rather than performing every step in a fixed sequence. The final interpretation depends on normalized ratios, locally validated cutoffs, specimen quality, and exclusion of other causes of prolonged clotting.
The paradox is worth emphasizing: LA prolongs clotting in the laboratory but is associated with clotting risk in patients. The assay measures interference with a test system, not the speed at which a person’s blood will clot in daily life.
A normal routine aPTT does not exclude lupus anticoagulant. Some LA antibodies affect dRVVT but not aPTT, and routine aPTT reagents may be relatively insensitive. Conversely, a prolonged aPTT is not automatically LA. Heparin, factor deficiencies, specific factor inhibitors, and other abnormalities can produce prolongation.
Sample handling is crucial. Platelet contamination can supply phospholipid and weaken an LA signal. Laboratories therefore prepare platelet-poor plasma, often with careful centrifugation. Delayed processing, freezing conditions, and incomplete medication information can also affect interpretation.
Because anticoagulant drugs act directly on clotting pathways, they can produce false-positive or false-negative LA patterns. The result should include a medication-aware comment rather than a simple unqualified label whenever interference is possible.
How Antibody Results Are Reported
Anticardiolipin and anti-beta-2 glycoprotein I are solid-phase immunoassays. They are less directly affected by anticoagulant drugs than LA tests, but their methods are not fully interchangeable.
Reports may use GPL or MPL units, units per milliliter, arbitrary units, or manufacturer-specific values. The laboratory’s own reference range must be used. A value cannot be compared reliably with a number from another assay unless the methods and calibration are known to align.
The 2023 ACR/EULAR classification framework defines moderate and high levels for specified enzyme-linked immunosorbent assays as 40–79 units and at least 80 units. These thresholds were developed for classification and should not be copied automatically onto every automated platform.
Interpretation should separate:
- Isotype: IgG and IgM are distinct results.
- Target: anticardiolipin and anti-beta-2 glycoprotein I are not duplicates.
- Magnitude: a weak value near the cutoff is less robust than a clearly elevated result.
- Persistence: a single positive may be transient.
- Method: assay design influences the number and cutoff.
A report marked “equivocal” or “borderline” identifies uncertainty near the threshold. It does not represent a partial diagnosis. The most appropriate response is often to review the reason for testing and repeat the same assay later if the result may change care.
Negative solid-phase antibodies do not exclude LA. Negative IgG results do not exclude IgM. A complete interpretation requires all ordered components, not the summary flag at the top of the report.
Combining Results Into an Antibody Profile
The panel becomes clinically useful when the separate tests are combined into a profile. Risk is not determined by simply counting every positive line, but established patterns do carry different levels of concern.
| Profile | General significance | Important qualification |
|---|---|---|
| All established markers negative | APS laboratory support is absent on this sample | Validity, timing, medication interference, and prior results still matter |
| Single low antibody positive | Often lower specificity and may be transient | Clinical event and repeat result determine relevance |
| Persistent moderate/high aCL or anti-β2GPI | Established laboratory evidence with greater potential significance | APS still requires clinical correlation |
| Persistent LA alone | Can represent a clinically important profile | Testing must be valid despite medication and other interference |
| Double positivity | Two established marker groups are positive | Level, isotype, persistence, and event history remain essential |
| Triple positivity | LA, aCL, and anti-β2GPI are all positive; often considered high risk | Each component must be confirmed and correctly measured |
Triple positivity refers specifically to the three established groups. It does not mean any three antibodies on an expanded panel. A person with three non-criteria IgA or phospholipid antibodies should not be assigned the same risk label.
A profile can also change between samples. For example, anticardiolipin IgG may remain strongly positive while LA changes from positive to indeterminate because the second sample was collected during direct oral anticoagulant therapy. That is not proof that the immune profile improved. The laboratory circumstances must be reconciled before the patient is reclassified from triple positive to single positive. In contrast, a low anticardiolipin result that disappears when repeated with the same method after recovery from infection is more consistent with transient reactivity.
Clinicians sometimes use the term “high-risk aPL profile” for persistent LA, double or triple positivity, or persistently high antibody levels. This phrase describes a pattern associated with greater concern; it is not a diagnosis and does not prescribe one treatment for every patient. A person’s prior event and bleeding risk still determine what prevention is reasonable.
Persistent LA is frequently associated with greater clinical risk than an isolated low solid-phase antibody. High IgG levels and combined established-marker positivity also raise concern. Isolated IgM can be relevant, but its association with thrombosis is often less consistent than IgG or LA and must be interpreted carefully.
The profile is only one part of risk. Prior thrombosis, systemic lupus erythematosus, smoking, hypertension, diabetes, estrogen exposure, surgery, immobility, pregnancy, and cancer can change the probability of a future event. A laboratory pattern should guide—not replace—clinical assessment.
From Positive Tests to APS Diagnosis
APS is diagnosed by connecting persistent antiphospholipid antibodies with a compatible clinical manifestation. Antibody positivity without such a manifestation is often described as antiphospholipid antibody carriage rather than APS.
The 2023 ACR/EULAR classification criteria require an entry condition and then use weighted clinical and laboratory domains. The clinical domains include venous, arterial, microvascular, obstetric, heart valve, and hematologic findings. The laboratory domains include LA and anticardiolipin or anti-beta-2 glycoprotein I IgG/IgM. Classification requires enough points in both clinical and laboratory domains.
These criteria were built to identify consistent research populations. Clinical diagnosis may be less restrictive, but it should not be casual. Current guidance emphasizes careful review of alternative causes and laboratory limitations rather than applying a point score mechanically to every patient.
A sound diagnostic assessment asks:
- Is the clinical event objectively documented?
- Does it fit an APS-associated pattern?
- Is at least one established marker present at a meaningful level?
- Is the result persistent on testing at least 12 weeks apart?
- Was LA testing technically valid?
- Do other diagnoses or provoking factors better explain the event?
A positive panel during an acute infection and a negative repeat does not establish APS. Persistent triple positivity after an unprovoked pulmonary embolism provides much stronger support. Persistent antibodies after a major trauma-related clot may still be important, but attribution and treatment duration require more judgment.
Diagnosis should also distinguish macrovascular, microvascular, and non-thrombotic manifestations. A leg deep vein thrombosis is a macrovascular venous event. Biopsy-supported small-vessel injury in the kidney is a different domain and may require nephrology input. Low platelets or heart valve thickening can occur with APS, but neither finding alone should be converted into a thrombotic diagnosis without the appropriate clinical and laboratory assessment.
Pregnancy diagnosis also depends on exact records. One early miscarriage is common and nonspecific. Defined recurrent losses, unexplained fetal death, or early delivery for severe placental insufficiency create a different level of suspicion. Laboratory findings cannot replace the obstetric details.
Timing, Medications, and Common Testing Errors
The best time to test is when the result can be interpreted safely and will affect care. Solid-phase antibodies can often be measured during anticoagulation, but LA testing becomes difficult.
Anticoagulant interference
Direct oral anticoagulants such as rivaroxaban, apixaban, edoxaban, and dabigatran can alter dRVVT and aPTT-based tests. Heparins and warfarin can also complicate results. The exact effect varies by drug, dose, time since the last dose, reagent, and laboratory strategy.
Never stop anticoagulation solely to obtain cleaner testing without a clinician-directed plan. The risk of an untreated recurrent clot can outweigh the value of immediate LA testing. Options may include delaying confirmation, drawing at a carefully selected trough, using drug-level information, applying validated neutralization methods, or relying temporarily on solid-phase antibodies.
Acute illness and thrombosis
Acute infection and inflammation can accompany transient antibodies. The acute clot itself, treatment started afterward, and hospital sample handling can make the initial profile difficult to interpret. An initial sample may still be useful, but a later confirmation is often essential.
The 12-week interval
Persistence requires tests on two occasions at least 12 weeks apart. Twelve weeks equals 84 days. A repeat at 11 weeks does not meet that interval even if it falls in a different calendar month. The second test should use the same marker set and, where possible, the same laboratory method.
Frequent mistakes
Common errors include:
- Ordering anticardiolipin alone and calling it a complete APS panel
- Omitting IgG or IgM isotypes
- Treating a routine aPTT as a full LA evaluation
- Accepting an LA result without reviewing anticoagulant medication
- Diagnosing APS from one weak positive result
- Repeating too soon
- Comparing values from different platforms as though they were identical
- Ordering broad non-criteria panels before completing established tests
The antiphospholipid antibody repeat testing guide covers the confirmation interval and method consistency in more detail.
What to Do With the Panel Results
A negative panel should lead to a validity check before APS is dismissed. Was the full panel performed? Was the patient taking a drug that could mask or mimic LA? Was there an earlier positive result? If testing was valid and complete, clinicians should investigate other causes of thrombosis or pregnancy complications.
A positive panel should be summarized precisely. Record the marker, isotype, value, units, cutoff, collection date, medication status, and whether the result is initial or persistent. Keep the original report because a future clinician cannot reconstruct assay details from “APS positive” in a problem list.
Follow-up may involve hematology, rheumatology, maternal-fetal medicine, neurology, nephrology, or another specialty depending on the event. The visit should address:
- Whether the patient has antibody positivity or APS
- Whether repeat testing is needed and when
- Whether the prior event requires anticoagulation regardless of APS status
- Which anticoagulant is appropriate if APS is established
- Whether aspirin has a justified role
- Plans for pregnancy, surgery, hospitalization, or estrogen-containing medication
- Control of smoking, blood pressure, diabetes, cholesterol, and immobility
A positive antibody result does not automatically justify lifelong anticoagulation in someone who has never had a clot. A negative repeat does not automatically justify stopping treatment after a serious thrombosis. Medication decisions depend on recurrence risk, bleeding risk, event type, and the entire profile.
Emergency symptoms require urgent assessment regardless of the last panel result. Sudden shortness of breath, chest pain, coughing blood, unilateral leg swelling, new speech difficulty, facial droop, one-sided weakness, severe sudden vision loss, or a cold painful limb may signal an acute clot. The antibody report can inform the emergency team, but imaging and immediate clinical evaluation establish the acute diagnosis.
A properly performed panel is best understood as a coordinated set of tests: one functional clotting evaluation and two antibody target groups, interpreted twice when confirmation is needed. That complete view provides far more reliable information than any isolated positive flag.
References
- An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies 2025 (Guideline)
- Lupus Anticoagulant Testing for Diagnosis of Antiphospholipid Syndrome: A Perspective Informed by Local Practice 2025 (Review)
- Guidelines on the investigation and management of antiphospholipid syndrome 2024 (Guideline)
- 2023 ACR/EULAR antiphospholipid syndrome classification criteria 2023 (Classification Criteria)
- Diagnosis and management of antiphospholipid syndrome 2024 (Review)
- Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances 2022 (Review)
Disclaimer
This article is educational and cannot determine whether a laboratory pattern represents APS or whether blood-thinning treatment is appropriate. Panel interpretation requires clinical records, repeat timing, assay details, medication review, and assessment of clotting and bleeding risks. Seek emergency care immediately for symptoms of a possible blood clot or stroke.
